Dr. Reddy's Laboratories, a major player in the pharmaceutical industry, reported a consolidated net profit of ₹221 crore for the quarter ending March 31, 2026, marking an 86% decline from ₹1,587 crore in the same quarter last year. The company's revenue also saw a 12% decrease, falling to ₹7,516 crore from ₹8,506 crore year-on-year. The board has recommended a final dividend of ₹8 per equity share for the financial year 2025-26, pending approval at the upcoming Annual General Meeting, with a record date set for July 10, 2026. Sequentially, the profit after tax decreased by 81% from ₹1,190 crore in Q3 FY26, while revenue declined 14% from ₹8,727 crore in the previous quarter. Despite the quarterly downturn, the company reported a 3% increase in total revenue for the entire fiscal year, reaching ₹33,593 crore compared to ₹32,553 crore the previous year. The decline in revenue was attributed to lower sales of Lenalidomide, price erosion in North America and Europe, and a one-time Shelf Stock Adjustment (SSA) impact of ₹450 crore. Gross margins also suffered, decreasing to 44.8% in Q4 FY26, down 1,074 basis points year-on-year, and to 52.8% for the full year, reflecting various market challenges.